p21-activated kinase family: promising new drug targets

References

• Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L. A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature. 1994;367:40–46.
   PubMed Web of Science ®Google Scholar
• Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R. PAK signaling in oncogenesis. Oncogene. 2009;28:2545–2555.
   PubMed Web of Science ®Google Scholar
• Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev. 2009;28:51–63.
   PubMed Web of Science ®Google Scholar
• Whale A, Hashim FN, Fram S, Jones GE, Wells CM. Signalling to cancer cell invasion through PAK family kinases. Front Biosci (Landmark Ed). 2011;16:849–864.
   PubMed Web of Science ®Google Scholar
• Rane CK, Minden A. P21 activated kinases: structure, regulation, and functions. Small GTPases. March 21, 2014. [Epub ahead of print.]
   Google Scholar
• King H, Nicholas NS, Wells CM. Role of p-21-activated kinases in cancer progression. Int Rev Cell Mol Biol. 2014;309:347–387.
   PubMed Web of Science ®Google Scholar
• Wells CM, Jones GE. The emerging importance of group II PAKs. Biochem J. 2010;425:465–473.
   PubMed Web of Science ®Google Scholar
• Szczepanowska J. Involvement of Rac/Cdc42/PAK pathway in cytoskeletal rearrangements. Acta Biochim Pol. 2009;56:225–234.
   PubMed Web of Science ®Google Scholar
• Ching YP, Leong VY, Wong CM, Kung HF. Identification of an autoinhibitory domain of p21-activated protein kinase 5. J Biol Chem. 2003;278:33621–33624.
   PubMed Web of Science ®Google Scholar
• Baskaran Y, Ng YW, Selamat W, Ling FT, Manser E. Group I and II mammalian PAKs have different modes of activation by Cdc42. EMBO Rep. 2012;13:653–659.
   PubMed Web of Science ®Google Scholar
• Ha BH, Davis MJ, Chen C, et al. Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate. Proc Natl Acad Sci U S A. 2012;109:16107–16112.
   Web of Science ®Google Scholar
• Menges CW, Sementino E, Talarchek J, et al. Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways. Mol Cancer Res. 2012;10:1178–1188.
   PubMed Web of Science ®Google Scholar
• Huynh N, Liu KH, Baldwin GS, He H. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways. Biochim Biophys Acta. 2010;1803:1106–1113.
   PubMed Web of Science ®Google Scholar
• Beeser A, Jaffer ZM, Hofmann C, Chernoff J. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J Biol Chem. 2005;280:36609–36615.
   PubMed Web of Science ®Google Scholar
• King AJ, Sun H, Diaz B, et al. The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature. 1998;396:180–183.
   PubMed Web of Science ®Google Scholar
• Tran NH, Frost JA. Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition. J Biol Chem. 2003;278:11221–11226.
   PubMed Web of Science ®Google Scholar
• He H, Huynh N, Liu KH, et al. P-21 activated kinase 1 knockdown inhibits beta-catenin signalling and blocks colorectal cancer growth. Cancer Lett. 2012;317:65–71.
   PubMed Web of Science ®Google Scholar
• Park MH, Kim DJ, You ST, et al. Phosphorylation of beta-catenin at serine 663 regulates its transcriptional activity. Biochem Biophys Res Commun. 2012;419:543–549.
   Web of Science ®Google Scholar
• Balasenthil S, Sahin AA, Barnes CJ, et al. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem. 2004;279:1422–1428.
   PubMedGoogle Scholar
• Zhao ZS, Lim JP, Ng YW, Lim L, Manser E. The GIT-associated kinase PAK targets to the centrosome and regulates Aurora-A. Mol Cell. 2005;20:237–249.
   PubMed Web of Science ®Google Scholar
• Edwards DC, Sanders LC, Bokoch GM, Gill GN. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol. 1999;1:253–259.
   PubMed Web of Science ®Google Scholar
• Vadlamudi RK, Li F, Barnes CJ, Bagheri-Yarmand R, Kumar R. p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. EMBO Rep. 2004;5:154–160.
   PubMed Web of Science ®Google Scholar
• Sanders LC, Matsumura F, Bokoch GM, de Lanerolle P. Inhibition of myosin light chain kinase by p21-activated kinase. Science. 1999;283:2083–2085.
   PubMed Web of Science ®Google Scholar
• Jin S, Zhuo Y, Guo W, Field J. p21-activated kinase 1 (Pak1)-dependent phosphorylation of Raf-1 regulates its mitochondrial localization, phosphorylation of BAD, and Bcl-2 association. J Biol Chem. 2005;280:24698–24705.
   PubMed Web of Science ®Google Scholar
• Ye DZ, Jin S, Zhuo Y, Field J. p21-Activated kinase 1 (PAK1) phosphorylates BAD directly at serine 111 in vitro and indirectly through Raf-1 at serine 112. PLoS One. 2011;6:e27637.
   Google Scholar
• Kichina JV, Goc A, Al-Husein B, Somanath PR, Kandel ES. PAK1 as a therapeutic target. Expert Opin Ther Targets. 2010;14:703–725.
   PubMed Web of Science ®Google Scholar
• Radu M, Semenova G, Kosoff R, Chernoff J. PAK signalling during the development and progression of cancer. Nat Rev Cancer. 2014;14:13–25.
   PubMed Web of Science ®Google Scholar
• Baker NM, Yee Chow H, Chernoff J, Der CJ. Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers. Clin Cancer Res. 2014;20:4740–4746.
   PubMed Web of Science ®Google Scholar
• Ye DZ, Field J. PAK signaling in cancer. Cell Logist. 2012;2:105–116.
   PubMedGoogle Scholar
• Ong CC, Jubb AM, Haverty PM, et al. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2011;108:7177–7182.
   PubMed Web of Science ®Google Scholar
• Bostner J, Skoog L, Fornander T, Nordenskjold B, Stal O. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res. 2010;16:1624–1633.
   PubMed Web of Science ®Google Scholar
• Bostner J, Ahnstrom Waltersson M, Fornander T, Skoog L, Nordenskjold B, Stal O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene. 2007;26:6997–7005.
   PubMed Web of Science ®Google Scholar
• Brown LA, Kalloger SE, Miller MA, et al. Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer. 2008;47:481–489.
   PubMed Web of Science ®Google Scholar
• Zhu G, Wang Y, Huang B, et al. A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells. Oncogene. 2012;31:1001–1012.
   PubMed Web of Science ®Google Scholar
• Carter JH, Douglass LE, Deddens JA, et al. PAK-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res. 2004;10:3448–3456.
   PubMed Web of Science ®Google Scholar
• Gong W, An Z, Wang Y, et al. P21-activated kinase 5 is overexpressed during colorectal cancer progression and regulates colorectal carcinoma cell adhesion and migration. Int J Cancer. 2009;125:548–555.
   PubMed Web of Science ®Google Scholar
• Chen S, Auletta T, Dovirak O, et al. Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther. 2008;7:1793–1802.
   PubMed Web of Science ®Google Scholar
• Kimmelman AC, Hezel AF, Aguirre AJ, et al. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A. 2008;105:19372–11937.
   PubMed Web of Science ®Google Scholar
• Begum A, Imoto I, Kozaki K, et al. Identification of PAK4 as a putative target gene for amplification within 19q13.12–q13.2 in oral squamous-cell carcinoma. Cancer Sci. 2009;100:1908–1916.
   PubMed Web of Science ®Google Scholar
• Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell. 2003;12:841–849.
   PubMed Web of Science ®Google Scholar
• Hirokawa Y, Tikoo A, Huynh J, et al. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J. 2004;10(1):20–26.
   Web of Science ®Google Scholar
• Fawdar S, Trotter EW, Li Y, et al. Targeted genetic dependency screen facilitates identification of actionable mutations in FGFR4, MAP3K9, and PAK5 in lung cancer. Proc Natl Acad Sci U S A. 2013;110:12426–12431.
   PubMed Web of Science ®Google Scholar
• Rudolph J, Crawford JJ, Hoeflich KP, Wang W. Inhibitors of p21-activated kinases (PAKs). J Med Chem. 2015;58:111–129.
   PubMed Web of Science ®Google Scholar
• Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53:549–554.
   PubMed Web of Science ®Google Scholar
• Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst. 1998;90:675–684.
   PubMed Web of Science ®Google Scholar
• Arrington AK, Heinrich EL, Lee W, et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 2012;13:12153–12168.
   PubMed Web of Science ®Google Scholar
• Bamford S, Dawson E, Forbes S, et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91:355–358.
   PubMed Web of Science ®Google Scholar
• Benhattar J, Losi L, Chaubert P, Givel JC, Costa J. Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology. 1993;104:1044–1048.
   PubMed Web of Science ®Google Scholar
• Chaudhary A, King WG, Mattaliano MD, et al. Phosphatidylinositol 3-kinase regulates Raf1 through PAK phosphorylation of serine 338. Curr Biol. 2000;10:551–554.
   PubMed Web of Science ®Google Scholar
• Frost JA, Steen H, Shapiro P, et al. Cross-cascade activation of ERKs and ternary complex factors by Rho family proteins. EMBO J. 1997;16:6426–6438.
   PubMed Web of Science ®Google Scholar
• Higuchi M, Onishi K, Kikuchi C, Gotoh Y. Scaffolding function of PAK in the PDK1-Akt pathway. Nat Cell Biol. 2008;10:1356–1364.
   PubMed Web of Science ®Google Scholar
• Li LH, Zheng MH, Luo Q, et al. P21-activated protein kinase 1 induces colorectal cancer metastasis involving ERK activation and phosphorylation of FAK at Ser-910. Int J Oncol. 2010;37:951–962.
   Web of Science ®Google Scholar
• Chow HY, Jubb AM, Koch JN, et al. p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res. 2012;72:5966–5975.
   PubMed Web of Science ®Google Scholar
• Tabusa H, Brooks T, Massey AJ. Knockdown of PAK4 or PAK1 inhibits the proliferation of mutant KRAS colon cancer cells independently of RAF/MEK/ERK and PI3K/AKT signaling. Mol Cancer Res. 2013;11:109–121.
   PubMed Web of Science ®Google Scholar
• He H, Shulkes A, Baldwin GS. PAK1 interacts with beta-catenin and is required for the regulation of the beta-catenin signalling pathway by gastrins. Biochim Biophys Acta. 2008;1783:1943–1954.
   Web of Science ®Google Scholar
• Arias-Romero LE, Villamar-Cruz O, Huang M, Hoeflich KP, Chernoff J. Pak1 kinase links ErbB2 to beta-catenin in transformation of breast epithelial cells. Cancer Res. 2013;73:3671–3682.
   PubMed Web of Science ®Google Scholar
• Xue J, Chen LZ, Li ZZ, Hu YY, Yan SP, Liu LY. MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4). Mol Cell Biochem. 2015;399:77–86.
   Web of Science ®Google Scholar
• Cheng Z, Liu F, Wang G, Li Y, Zhang H, Li F. miR-133 is a key negative regulator of CDC42-PAK pathway in gastric cancer. Cell Signal. 2014;26:2667–2673.
   PubMed Web of Science ®Google Scholar
• Schurmann A, Mooney AF, Sanders LC, et al. p21-activated kinase 1 phosphorylates the death agonist BAD and protects cells from apoptosis. Mol Cell Biol. 2000;20:453–461.
   PubMed Web of Science ®Google Scholar
• Gnesutta N, Qu J, Minden A. The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. J Biol Chem. 2001;276:14414–14419.
   PubMed Web of Science ®Google Scholar
• Wang X, Gong W, Qing H, et al. p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells. Tumour Biol. 2010;31:575–582.
   PubMedGoogle Scholar
• Cotteret S, Jaffer ZM, Beeser A, Chernoff J. p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol. 2003;23(16):5526–5539.
   PubMed Web of Science ®Google Scholar
• Wu X, Carr HS, Dan I, Ruvolo PP, Frost JA. p21 activated kinase 5 activates Raf-1 and targets it to mitochondria. J Cell Biochem. 2008;105:167–175.
   PubMed Web of Science ®Google Scholar
• Vadlamudi RK, Bagheri-Yarmand R, Yang Z, et al. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell. 2004;5:575–585.
   PubMed Web of Science ®Google Scholar
• Mazumdar A, Kumar R. Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett. 2003;535:6–10.
   PubMed Web of Science ®Google Scholar
• Jakobi R, McCarthy CC, Koeppel MA, Stringer DK. Caspase-activated PAK-2 is regulated by subcellular targeting and proteasomal degradation. J Biol Chem. 2003;278:38675–38685.
   PubMed Web of Science ®Google Scholar
• Rudel T, Bokoch GM. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2. Science. 1997;276:1571–1574.
   PubMed Web of Science ®Google Scholar
• Rudel T, Zenke FT, Chuang TH, Bokoch GM. p21-activated kinase (PAK) is required for Fas-induced JNK activation in Jurkat cells. J Immunol. 1998;160:7–11.
   PubMed Web of Science ®Google Scholar
• Li X, Wen W, Liu K, et al. Phosphorylation of caspase-7 by p21-activated protein kinase (PAK) 2 inhibits chemotherapeutic drug-induced apoptosis of breast cancer cell lines. J Biol Chem. 2011;286:22291–22299.
   Web of Science ®Google Scholar
• Kiosses WB, Daniels RH, Otey C, Bokoch GM, Schwartz MA. A role for p21-activated kinase in endothelial cell migration. J Cell Biol. 1999;147:831–844.
   PubMed Web of Science ®Google Scholar
• Dharmawardhane S, Sanders LC, Martin SS, Daniels RH, Bokoch GM. Localization of p21-activated kinase 1 (PAK1) to pinocytic vesicles and cortical actin structures in stimulated cells. J Cell Biol. 1997;138:1265–1278.
   PubMed Web of Science ®Google Scholar
• Sells MA, Pfaff A, Chernoff J. Temporal and spatial distribution of activated Pak1 in fibroblasts. J Cell Biol. 2000;151:1449–1458.
   PubMed Web of Science ®Google Scholar
• Sells MA, Knaus UG, Bagrodia S, Ambrose DM, Bokoch GM, Chernoff J. Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr Biol. 1997;7:202–210.
   PubMed Web of Science ®Google Scholar
• Sells MA, Boyd JT, Chernoff J. p21-activated kinase 1 (Pak1) regulates cell motility in mammalian fibroblasts. J Cell Biol. 1999;145:837–849.
   PubMed Web of Science ®Google Scholar
• Vadlamudi RK, Adam L, Wang RA, et al. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem. 2000;275:36238–36244.
   PubMed Web of Science ®Google Scholar
• Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer. 2006;118:2703–2710.
   PubMed Web of Science ®Google Scholar
• Delorme V, Machacek M, DerMardirossian C, et al. Cofilin activity downstream of Pak1 regulates cell protrusion efficiency by organizing lamellipodium and lamella actin networks. Dev Cell. 2007;13:646–662.
   PubMed Web of Science ®Google Scholar
• Misra UK, Deedwania R, Pizzo SV. Binding of activated alpha2-macroglobulin to its cell surface receptor GRP78 in 1-LN prostate cancer cells regulates PAK-2-dependent activation of LIMK. J Biol Chem. 2005;280:26278–26286.
   PubMed Web of Science ®Google Scholar
• Daub H, Gevaert K, Vandekerckhove J, Sobel A, Hall A. Rac/Cdc42 and p65PAK regulate the microtubule-destabilizing protein stathmin through phosphorylation at serine 16. J Biol Chem. 2001;276:1677–1680.
   PubMed Web of Science ®Google Scholar
• Wittmann T, Bokoch GM, Waterman-Storer CM. Regulation of microtubule destabilizing activity of Op18/stathmin downstream of Rac1. J Biol Chem. 2004;279:6196–6203.
   PubMed Web of Science ®Google Scholar
• Vadlamudi RK, Barnes CJ, Rayala S, et al. p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B. Mol Cell Biol. 2005;25:3726–3736.
   PubMed Web of Science ®Google Scholar
• Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med. 2008;29:290–308.
   PubMed Web of Science ®Google Scholar
• Li Q, Mullins SR, Sloane BF, Mattingly RR. p21-Activated kinase 1 coordinates aberrant cell survival and pericellular proteolysis in a three-dimensional culture model for premalignant progression of human breast cancer. Neoplasia. 2008;10:314–329.
   PubMed Web of Science ®Google Scholar
• Rider L, Oladimeji P, Diakonova M. PAK1 regulates breast cancer cell invasion through secretion of matrix metalloproteinases in response to prolactin and three-dimensional collagen IV. Mol Endocrinol. 2013;27:1048–1064.
   Google Scholar
• Wang XX, Cheng Q, Zhang SN, et al. PAK5-Egr1-MMP2 signaling controls the migration and invasion in breast cancer cell. Tumour Biol. 2013;34:2721–2729.
   PubMedGoogle Scholar
• Han ZX, Wang XX, Zhang SN, et al. Downregulation of PAK5 inhibits glioma cell migration and invasion potentially through the PAK5-Egr1-MMP2 signaling pathway. Brain Tumor Pathol. 2014;31:234–241.
   Web of Science ®Google Scholar
• Kesanakurti D, Chetty C, Rajasekhar Maddirela D, Gujrati M, Rao JS. Functional cooperativity by direct interaction between PAK4 and MMP-2 in the regulation of anoikis resistance, migration and invasion in glioma. Cell Death Dis. 2012;3:e445.
   Web of Science ®Google Scholar
• Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8:1223–1234.
   PubMed Web of Science ®Google Scholar
• Rettig M, Trinidad K, Pezeshkpour G, et al. PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. PLoS One. 2012;7:e42012.
   Web of Science ®Google Scholar
• Guilluy C, Zhang Z, Bhende PM, et al. Latent KSHV infection increases the vascular permeability of human endothelial cells. Blood. 2011;118:5344–5354.
   Web of Science ®Google Scholar
• Kiosses WB, Hood J, Yang S, et al. A dominant-negative p65 PAK peptide inhibits angiogenesis. Circ Res. 2002;90:697–702.
   PubMed Web of Science ®Google Scholar
• Frost JA, Khokhlatchev A, Stippec S, White MA, Cobb MH. Differential effects of PAK1-activating mutations reveal activity-dependent and -independent effects on cytoskeletal regulation. J Biol Chem. 1998;273:28191–28198.
   PubMed Web of Science ®Google Scholar
• Hayashi ML, Rao BS, Seo JS, et al. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci U S A. 2007;104:11489–11494.
   PubMed Web of Science ®Google Scholar
• He H, Hirokawa Y, Manser E, Lim L, Levitzki A, Maruta H. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J. 2001;7:191–202.
   PubMed Web of Science ®Google Scholar
• Uprichard SL. The therapeutic potential of RNA interference. FEBS Lett. 2005;579:5996–6007.
   PubMed Web of Science ®Google Scholar
• Nheu TV, He H, Hirokawa Y, et al. The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Cancer J. 2002;8:328–336.
   PubMed Web of Science ®Google Scholar
• Maroney AC, Finn JP, Connors TJ, et al. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem. 2001;276:25302–25308.
   PubMed Web of Science ®Google Scholar
• Maksimoska J, Feng L, Harms K, et al. Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J Am Chem Soc. 2008;130:15764–15765.
   Web of Science ®Google Scholar
• Guo C, McAlpine I, Zhang J, et al. Discovery of pyrroloaminopyrazoles as novel PAK inhibitors. J Med Chem. 2012;55:4728–4739.
   PubMed Web of Science ®Google Scholar
• Murray BW, Guo C, Piraino J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010;107:9446–9451.
   PubMed Web of Science ®Google Scholar
• Licciulli S, Maksimoska J, Zhou C, et al. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated schwannomas. J Biol Chem. 2013;288:29105–29114.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang J, Guo Q, et al. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett. 2012;317:24–32.
   PubMed Web of Science ®Google Scholar
• Deacon SW, Beeser A, Fukui JA, et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol. 2008;15:322–331.
   PubMedGoogle Scholar
• Viaud J, Peterson JR. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther. 2009;8:2559–2565.
   PubMed Web of Science ®Google Scholar
• Hofmann C, Shepelev M, Chernoff J. The genetics of Pak. J Cell Sci. 2004;117 Pt 19:4343–4354.
   Google Scholar